Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma
Neuro-Oncology · 01.12.2025 · 27 (12) · 3189-3199
DOI: 10.1093/neuonc/noaf184 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, online erschienen am 16.08.2025. Verfasst von Thomas J Kaley und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Benzimidazoles, Aminopyridines, Meningioma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Background
Central nervous system (CNS) tumors are associated with considerable morbidity and high mortality. Cyclin-dependent kinases (CDKs) regulate cell division in cancer, and CDK4/6 inhibitors are used for the treatment of breast cancer, representing an attractive therapy for different tumor types.
Methods
Here, we report mature results of a multicenter basket trial exploring the CDK4/6 inhibitor abemaciclib in patients with recurrent CNS tumors, including patients with glioma, primary CNS lymphoma, meningioma, and ependymoma. We expanded our cohort of meningioma patients based on preliminary evidence for activity. Patients were treated with 200 mg oral abemaciclib twice daily for days 1–28, following FDA recommendations for breast cancer. Primary outcomes included radiographic response rates and progression-free survival (PFS) at 6 months post-treatment. We also evaluated overall survival (OS) and toxicity. Exploratory outcomes included next-generation sequencing of tumor biopsies.
Results
Most cohorts did not demonstrate activity with the exception of the cohort of patients with recurrent meningioma, including patients with grade 2 or 3 disease (19/22 meningioma patients). In that group, the median PFS was 15 months (95% CI: 6.5, not reached) and median OS was 32.9 months (95% CI: 10.7, not reached); the 6-month PFS was 68.2% (95% CI: 51.3%, 90.7%). All 22 patients were evaluable for radiographic response, showing stable disease in 16/22 (73%) and progressive disease in 6/22 patients (27%).
Conclusion
Our data suggest that abemaciclib improves PFS and OS in patients with advanced meningioma. The 6-month PFS with abemaciclib in this study (68.2%) exceeded RANO proposed benchmarks for activity (49%).
Trial registration
NCT03220646
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Weill Cornell Medical College, New York, New York, USA.
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Human Oncology and Pathogenesis Program, Sloan Kettering Institute, New York, NY, 10065, USA.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Lehigh Valley Hospital-Cedar Crest, Allentown, PA, USA.
- Hartford HealthCare Cancer Institute, Plainville, CT, USA.
ORCID-Profile: Thomas J Kaley, Ahmad Daher, Eli L Diamond, Elena Pentsova
Förderung
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Kaley, T. J., Grommes, C., Coffee, E., Young, R. J., Morrison, T., Daher, A., Schaff, L. R., Deng, Y., Nandakumar, S., Diamond, E. L., DeAngelis, L. M., Panageas, K. S., Gavrilovic, I., Lin, A., Pentsova, E., Stone, J., Santomasso, B. D., Piotrowski, A. F., Nair, S., …, & Mellinghoff, I. K. (2025). Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. Neuro-Oncology, 27(12), 3189-3199. https://doi.org/10.1093/neuonc/noaf184
Vancouver
Kaley TJ, Grommes C, Coffee E, Young RJ, Morrison T, Daher A, et al. Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. Neuro-Oncology. 2025;27(12):3189-3199. doi:10.1093/neuonc/noaf184
BibTeX
@article{Kaley2025,
author = {Kaley, Thomas J and Grommes, Christian and Coffee, Elizabeth and Young, Robert J and Morrison, Tara and Daher, Ahmad and Schaff, Lauren R and Deng, Yufei and Nandakumar, Subhiksha and Diamond, Eli L and DeAngelis, Lisa M and Panageas, Katherine S and Gavrilovic, Igor and Lin, Andrew and Pentsova, Elena and Stone, Jacqueline and Santomasso, Bianca D and Piotrowski, Anna F and Nair, Suresh and Schultz, Nikolaus and Reiner, Anne S and Mellinghoff, Ingo K},
title = {Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {12},
pages = {3189--3199},
doi = {10.1093/neuonc/noaf184}
}
EUVIMED